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Variations in Multiple Syndromic 
Deafness Genes Mimic Non-
syndromic Hearing Loss
G. Bademci1, F. B. Cengiz1, J. Foster II1, D. Duman2, L. Sennaroglu3, O. Diaz-Horta1, 
T. Atik4, T. Kirazli5, L. Olgun6, H. Alper7, I. Menendez1, I. Loclar8, G. Sennaroglu9, S. Tokgoz-
Yilmaz9, S. Guo1, Y. Olgun6, N. Mahdieh10, M. Bonyadi11, N. Bozan12, A. Ayral12, F. Ozkinay4, 
M. Yildirim-Baylan13, S. H. Blanton1,14 & M. Tekin1,14
The genetics of both syndromic (SHL) and non-syndromic hearing loss (NSHL) is characterized by a high 
degree of genetic heterogeneity. We analyzed whole exome sequencing data of 102 unrelated probands 
with apparently NSHL without a causative variant in known NSHL genes. We detected five causative 
variants in different SHL genes (SOX10, MITF, PTPN11, CHD7, and KMT2D) in five (4.9%) probands. 
Clinical re-evaluation of these probands shows that some of them have subtle syndromic findings, while 
none of them meets clinical criteria for the diagnosis of the associated syndrome (Waardenburg (SOX10 
and MITF), Kallmann (CHD7 and SOX10), Noonan/LEOPARD (PTPN11), CHARGE (CHD7), or Kabuki 
(KMT2D). This study demonstrates that individuals who are evaluated for NSHL can have pathogenic 
variants in SHL genes that are not usually considered for etiologic studies.
Hearing loss (HL) affects approximately 1 in 650 children, more than half of which is attributed to genetic fac-
tors1. Based on distinctive clinical features, approximately 30% of genetic HL is syndromic (SHL) and 70% is 
non-syndromic (NSHL)2. To date, more than 145 NSHL loci have been identified3 and HL has been reported as a 
feature in more than 400 syndromes4.
Identifying the specific genetic cause of HL in an individual is difficult due to extensive genetic and clinical 
heterogeneity. The same pathogenic variant may present differently in either the severity of HL or in the overall 
clinical presentation5,6. In this study, we searched for causative DNA variants in a large cohort of individuals who 
apparently were diagnosed with NSHL after excluding variants in known NSHL genes (Supplementary Table S1).
Results
On average, each exome had 99%, 95% and 89% of mappable bases of the Gencode defined exome represented 
by coverage of 1X, 5X, and 10X reads, respectively. We detected heterozygous pathogenic variants in five different 
SHL genes that can explain HL in five (4.9%) Turkish families (Table 1). The pathogenic variants MITF (MIM 
156845) c.328C > T7,8 (Waardenburg syndrome type II; MIM 193510), SOX10 (Kallmann syndrome) c.481C > T9, 
CHD7 (MIM 608892) c.5050G > A9–12 (CHARGE syndrome; MIM 214800 and Kallmann syndrome; MIM 
612370), PTPN11 (MIM 176876) c.1492C > T13–16 (LEOPARD syndrome; MIM 151100), and KMT2D (MIM 
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602113) c.13259G > A17 (Kabuki syndrome; MIM 147920) had all been previously reported in patients with syn-
dromic findings. All the identified variants were confirmed with Sanger sequencing in probands and tested for in 
available family members (Fig. 1).
In family 78, along with the proband, the deaf brother and normal hearing mother both carried the MITF 
c.328C > T variant. Phenotypic features of the 11-year-old female proband and her 7-year-old brother included 
only congenital severe to profound HL without pigmentary changes in hair, eyes, or skin. The mother was not 
available for clinical evaluation but denied having pigmentary changes or HL.
In family 94, while both affected children carried the putative pathogenic variant (SOX10 c.481C > T), the 
mother did not and the father was unavailable. The mother denied HL in the deceased father. The proband was 
a 9-year-old female with profound HL. She did not have pigmentary skin, hair, or eye changes. She had a normal 
Family ID Gene Transcript ID cDNA Protein ClinVar HGMD ExAC PolyPhen2 SIFT
Mutation 
Taster ACMG
78 MITF NM_000248.3 c.328C > T p.R110X n.a. P n.a. n.a. n.a. DC P
94 SOX10 NM_006941.3 c.481C > T p.R161C n.a. P n.a. probably-damaging DM DC LP
694 CHD7 NM_017780.3 c.5050G > A p.G1684S n.a. P n.a. probably-damaging DM DC P
713 PTPN11 NM_002834.3 c.1492C > T p.R498W P P n.a. probably-damaging DM DC P
859 KMT2D NM_003482.3 c.13259G > A p.R4420Q n.a. P 2.54E-05 possibly-damaging DM DC LP
Table 1.  Causative variants identified in this study. n.a.: not available, P: Pathogenic, LP: Likely Pathogenic, 
DC: Disease Causing, DM: Damaging, ExAC: Exome Aggregation Consortium, HGMD: Human Gene 
Mutation Database, ACMG: American College of Medical Genetics (Richards et al.)60.
Figure 1. Pedigrees and electropherograms of five families with a causative DNA variant and craniofacial 
appearance of probands 694, 713, and 859. Black squares and circles denote affected males and females with 
hearing loss, respectively. Proband 694 has a square face with prominent nasal bridge and columella. Other 
facial features of CHARGE syndrome such as facial palsy or outer ear findings are missing. Proband 713 
has hypertelorism and slightly low-set, posteriorly rotated ears. Other facial features of Noonan/LEOPARD 
syndrome such as epicanthal folds or ptosis is missing. Proband 859 shows telechantus, epicanthal folds, slightly 
downslanting palpebral fissures with short columella. Facial features of Kabuki syndrome including long 
palpebral fissures with eversion of the lateral lower eyelid, arched and broad eyebrows with the lateral third 
displaying sparseness, and large or prominent ears are missing.
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neurological examination. The 11-year-old brother had congenital profound deafness with no pigmentary alter-
ations in eyes, skin, or hair.
The proband in family 694 (CHD7 c.5050G > A variant) had congenital profound deafness associated with 
inner ear anomalies. At age 18 years her height and weight measured 165 cm and 60 kg, respectively; both were 
between the 50th and 75th centiles. She was at Tanner 5 stage for puberty and had her menarche at age 14 years. 
She did not have eye anomalies or a heart defect. She reported normal smelling. She did not have a history of nasal 
obstruction, nasal discharge, or otitis media. A nasogastric catheter was successfully passed through both nasal 
openings. While she had mild facial features of CHARGE syndrome (Fig. 1), she did not have other features of 
CHARGE or Kallmann syndromes (Table 2).
In family 713, the proband and his father carried the PTPN11 c.1492C > T variant. The proband was a 
4-year-old boy with congenital profound deafness. A thorough clinical re-evaluation of the proband detected 
minor craniofacial features without reaching diagnostic criteria of Noonan or LEOPARD syndromes (Fig. 1, 
Table 3)18–22. Father denied having HL and lentigines but was not available for clinical evaluation.
The proband in family 859 had the the KMT2D c.13259G > A variant and was a 1-year-old male with pro-
found deafness associated with bilateral cochlear aplasia. The patient was on target for neuromotor development 
and growth except for speech delay. Further clinical evaluation detected only telecanthus with bilateral epicanthal 
folds without findings of Kabuki syndrome (Fig. 1). The mother carried the same variant but did not have HL, 
cognitive problems, or distinctive findings of Kabuki syndrome.
Discussion
In this study, we detected pathogenic variants in MITF, SOX10, CHD7, PTPN11, and KMT2D in patients who 
were diagnosed as having NSHL. While these genes have been implicated in various forms of SHL, they were 
not reported to cause NSHL. Re-evaluation of probands shows that some of them exhibit subtle syndromic find-
ings not sufficient to make the clinical diagnosis of the associated syndrome (Supplementary Tables S2 to S5). 
Importantly, in several families, other individuals carried the same variant but had normal hearing.
Waardenburg syndrome (WS) is the most common type of autosomal dominant SHL with a frequency of 
1/40,000 in the general population23. WS is primarily characterized by HL and pigmentation anomalies in eyes, 
skin, and hair23,24. While there are additional findings affecting face, limbs, or gastrointestinal system in WS 
types I, III, and IV, WS type II presents only with HL and pigmentary anomalies (Supplementary Table S2). One 
Chinese and one Caucasian patient with typical pigmentary changes and deafness consistent with WS type II have 
been reported to be heterozygous for the MITF c.328C > T variant7,8. SOX10 variants are known to cause WS 
types II and IV (Hirschsprung disease as an additional finding) (MIM 613266), PCWH (peripheral demyelinating 
neuropathy, central demyelinating leukodystrophy, Waardenburg syndrome, and Hirschsprung disease) (MIM 
Asakura et al.,10 
Fujita et al.12 Husu et al.11 Marcos et al.9 Proband 694
Major Criteria 8.5 yo, F 8 yo, F 39 yo, M 18 yo, F
1. Coloboma, micropthalmia − − − − 
2. Choanal atresia or stenosis − − − − 
3.  Characteristic external ear anomaly, middle/
inner ear malformations, mixed deafness
+ 
 (abnormal 
semicircular canals)
+ 
(hypoplastic/absent 
semicircular canals)
n.a.
+ 
(bilateral cochlear 
incomplete partition 
type I, semicircular 
canal dysplasia)
4. Cranial nerve dysfunction
+ 
(aplasia of olfactory 
bulb)
+ 
 (vestibular dysfunction, 
swallowing problems, 
sensorineural HL)
+ 
 (anosmia, 
HL)
+ 
 (sensorineural HL)
Minor Criteria
 1. Cardiovascular malformations + + + − 
 2. Tracheo-oesophageal defects n.a. n.a. n.a. − 
 3.  Genital hypoplasia or delayed pubertal 
development − n.a.
+ 
(genital 
hypoplasia)
− 
 4. Cleft lip and/or palate + 
+ 
(unilateral cleft lip and 
palate)
− − 
 5. Developmental delay + + + 
+ 
 (speech and mild 
gross motor)
 6. Growth retardation + + n.a. − 
 7. Characteristic face + + n.a. +  (mild facial features)
Table 2.  Phenotype of patients with the CHD7 c.5050G > A variant based on Blake’s (Blake et al.)18 
CHARGE criteria*. n.a.: not available, yo: years old, HL: Hearing loss. * For diagnosis of typical CHARGE 4 
major or 3 major + 3 minor criteria are needed. Probable/possible CHARGE syndrome: 1 or 2 major and several 
minor criteria.
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609136), and Kallmann syndrome with deafness25. It is interesting to note that two patients with SOX10 muta-
tions resembling NSHL and inner ear anomalies were reported23. SOX10 c.481C > T has been previously reported 
in a patient with Kallmann syndrome9. Our patients with MITF and SOX10 variants did not have any of the 
pigmentary or neurological findings reported in WS and SOX10-related disorders. Formal evaluation of anosmia 
and hypogonadism reported in these syndromes are difficult to assess in young children and was not attempted.
CHARGE syndrome is autosomal dominant condition with a prevalence of 1 in 10,000 and is character-
ized by Coloboma of the eye, Heart defects, Atresia of the choanae, Retardation of growth and/or development, 
Genital and/or urinary tract abnormalities, and Ear anomalies and/or deafness26,27. Congenital anomalies are 
usually detected after birth. Overall psychomotor milestones from birth to age of 4 years can be severely delayed, 
although half of the children with CHARGE syndrome at primary-school age may have satisfactory intellectual 
ability28. Pathogenic variants in CHD7 cause CHARGE syndrome and hypogonadotropic hypogonadism 5 with 
anosmia (a.k.a. Kallmann syndrome) or without anosmia (MIM 612370). CHD7 c.5050G > A has been previ-
ously reported to cause CHARGE syndrome (Table 2)9–11,20. Studies have shown that semicircular canal atresia 
is a major finding of CHARGE and the patients with semicircular canal atresia should be screened for causative 
CHD7 variants29.
Noonan syndrome (NS) is an autosomal dominant condition seen 1 in 1,000–2,500 live births. It is character-
ized by distinctive facial features (low-set, posteriorly rotated ears with fleshy helices, hypertelorism, eyelid pto-
sis, downslanting palpebral fissures and epicanthal folds), postnatal growth reduction, congenital heart defects, 
hypertrophic cardiomyopathy, webbing of the neck, and skeletal anomalies30. The facial characteristics are usually 
prominent in early and middle childhood and more subtle in adulthood. Birth weight and length are usually 
normal. Growth failure is often apparent from the first year of life31. Cardiac abnormalities are present in 50–80% 
of individuals with NS. Median age at diagnosis for hypertrophic cardiomyopathy is five months32,33. LEOPARD 
syndrome (LS; multiple Lentigines and café-au-lait spots, Electrocardiographic-conduction abnormalities, 
Ocular hypertelorism/obstructive cardiomyopathy, Pulmonary stenosis, Abnormalities of the genitalia in males, 
Retardation of growth, and Deafness) is characterized by multiple lentigines and NS features. Pathogenic variants 
in PTPN11 are the most common cause of Noonan and LEOPARD syndromes. The c.1492C > T variant is located 
in exon 13 which is a hot spot region for this gene. This variant has previously been reported in individuals with 
LEOPARD syndrome with variable phenotypic features including multiple lentigines, hypertrophic cardiomyo-
pathy, dysmorphic facial features and variable degree of cognitive deficits (Table 3)13–16,34.
Kabuki syndrome (KS) is a rare autosomal dominant disorder and is characterized by five cardinal manifesta-
tions: a distinctive face (elongated palpebral fissures with eversion of the lateral third of the lower eyelid, arched 
and broad eyebrows with the lateral third displaying sparseness or notching, short columella with depressed nasal 
tip, and large, prominent, or cupped ears), skeletal anomalies, digit abnormalities, mild-to-moderate intellectual 
disability and postnatal growth retardation. While growth is normal at birth, growth failure occurs during the first 
Sarkozy et al.16 Sarkozy et al.16 Digilio et al.34 Kratz et al.15 Edwards et al. 14 Proband 713
Cardinal Features of Noonan/
LEOPARD syndrome 2 yo, F 34 yo, F < 1 yo, n.a. 1 < yo, M 5 yo, M 4 yo, M
Multiple Lentigines − − + n.a. − − 
Cardiac abnormalities, 
particularly hypertrophic 
cardiomyopathy
+ 
(h.c.m.)
+ 
(h.c.m.)
+ 
(h.c.m.)
+ 
(h.c.m.)
+ 
 (pulmonic valve 
stenosis)
− 
Poor linear growth/short 
stature n.a. n.a. + n.a. + 
−  
(height is at the 50th 
centile)
Pectus deformity n.a. n.a. n.a. − 
+ 
(mild pectus 
deformity)
− 
Dysmorphic facial features, 
including widely spaced eyes 
and ptosis
+ + n.a. − 
+ 
 (mild dysmorphic 
facial features)
mild dysmorphic 
facial features 
(hypertelorism and 
low set posteriorly 
rotated ears)
Additional features occurring frequently in LEOPARD syndrome
  Variable degree of 
cognitive deficits + + n.a. n.a.
+ 
(mild global 
developmental 
delay)
− 
 Sensorineural hearing loss − − − − − + 
 Cryptorchidism n.a.* n.a.* n.a. n.a. + − 
 Skeletal anomalies n.a. n.a. n.a. − n.a. − 
 Café-au-lait macules + − + n.a. − − 
 Other Information − Patient 1’s mother − 
Died at 2 months 
with juvenile 
myelomonocytic 
leukemia
− − 
Table 3.  Phenotypic features reported in individuals carrying PTPN11 p.R498W variant. n.a.: not available, 
n.a.* : not applicable, h.c.m.: hypertrophic cardiomyopathy, yo: years old, M: Male, F: Female.
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year of life and becomes more marked with increasing age20. Hearing loss is seen in up to 40% of patients, mostly 
due to recurrent otitis media; sensorineural hearing loss is a rare finding in patients with KS35. Pathogenic variants 
in KMT2D and KDM6A (MIM 300128) are only the known causes of the disorder17. The KMT2D c.13259G > A 
variant has been reported previously in a Korean 3-year-old female with typical facial features including long 
palpebral fissures with everted lower eyelids, large dysplastic ears, arched eyebrows, flat nasal tip, as well as prom-
inent digital pads, developmental delay and hypotonia without HL17 (the variant’s identity was confirmed by the 
corresponding author via personal communication). Neither parent carried the same variant.
Known examples of genes that can cause both SHL and NSHL include MYO7A (MIM 276903), USH1C (MIM 
605242), PCDH15 (MIM 605514), CDH23 (MIM 605516), CIB2 (MIM 605564), DFNB31 (MIM 607928) for 
Usher syndrome (MIM 276900; 276904; 602083; 601067; 614869; 611383), SLC26A4 (MIM 605646) for Pendred 
syndrome (MIM 274600), ACTG1 (MIM 102560) for Baraitser-Winter syndrome 2 (MIM 614583), TBC1D24 
(MIM 613577) for DOOR syndrome (MIM 220500), KARS (MIM 601421) for Charcot-Marie-Tooth disease, 
recessive intermediate B (MIM 613641) and COL11A2 (MIM 120290) for Stickler syndrome (MIM 184840)36–46. 
These genes are usually included in gene panels developed for deafness. SLC26A4 is one of the most common 
genes causing autosomal recessive hearing loss with enlarged vestibular aqueduct or Pendred syndrome5,6,47. Even 
the same pathogenic SLC26A4 variant can cause nonsyndromic deafness or Pendred syndrome, exemplifying 
variable phenotypic expressivity of the same gene48. Numerous functional studies of SLC26A4 pathogenic variants 
suggest that different mechanisms, including endoplasmic reticulum retention and defective plasma membrane 
targeting of pendrin, residual function of the pendrin, and additional genetic and/or environmental factors might 
play role in pathogenesis49–51.
Our study shows that variants in at least five SHL genes can mimic NSHL. The origin of the variable pheno-
types caused by the same variants may be genetic or environmental modifiers. It should be noted that some of the 
syndromic findings may be age dependent, such as retinitis pigmentosa in Usher syndrome or delayed puberty 
in Kallmann syndrome, and cannot be detected in a young child with HL. Some children may only have subtle 
phenotypic features of a syndrome, such as mild facial features of CHARGE or Noonan syndrome without meet-
ing diagnostic criteria. Clinical investigation for every potential finding of over 400 syndromes is not practical 
during the etiological evaluation of an individual with HL. Moreover, laboratory evaluations would yield equiv-
ocal results as recently reported for Jervell and Lange-Nielsen syndrome (MIM 220400) in which interpretation 
of EKG findings was complicated by sinus arrhythmia52. We recommend that consideration be given to inclusion 
of all genes known to cause any form of HL in gene panels developed for hereditary deafness. Alternatively 
all-inclusive genome analysis such as whole exome or whole genome sequencing should be considered when 
deafness gene panel studies prove inconclusive.
Methods
Statement of Ethics. This study was approved by the University of Miami Institutional Review Board 
(USA), the Growth and Development Research Ethics Committee (Iran), and Ankara University Medical School 
Ethics Committee (Turkey). Methods were carried out in accordance with the approved guidelines. A signed 
informed consent form was obtained from each participant or, in the case of a minor, from parents.
Subjects. This study includes 102 probands selected from a larger cohort that has been found to be negative 
for all known NSHL genes initially by Sanger sequencing (for variants in GJB2 and mtDNA 1555A > G) and sub-
sequently via whole exome sequencing (for a list of screened genes see Supplementary Table S1). Families were 
from Turkey (77), Iran (18) and the USA (7). Probands were the only affected individuals in 54 families (simplex); 
there were at least 2 affected siblings born to unaffected parents in the remaining 48 families (multiplex) suggest-
ing autosomal recessive inheritance. In all cases, HL was congenital or prelingual in onset with a severity ranging 
from severe to profound. Clinical evaluations of all probands were performed by both an otorhinolaryngologist 
and a clinical geneticist. These evaluations included a thorough physical examination, otoscopy, and ophthalmo-
scopy. An EKG, urinalysis, and, when available, high resolution CT of the temporal bone or MRI were performed 
in probands. Blood was collected from probands and family members (parents and siblings) when available and 
DNA was extracted from peripheral leukocytes by standard protocols.
Whole-Exome Sequencing and Bioinformatic Analysis. Agilent SureSelect Human All Exon 50 Mb 
and a HiSeq 2000 instrument (Illumina) were used for capture and sequencing based on our previously pub-
lished protocol47. Variants were called using FreeBayes53. After overall quality checks, Genesis 2.0 (https://www.
genesis-app.com/) was used for variant filtering. We filtered variants in all morbid OMIM genes (except for the 
previously screened known NSHL genes -Supplemental Table S1) with minor allele frequency thresholds of 0.005 
for recessive and 0.0005 for dominant variants as recommended54. For allele frequencies we used ExAC (http://
exac.broadinstitute.org/) and EVS (http://evs.gs.washington.edu/EVS/) databases as well as our internal whole 
exome sequencing database that includes more than 300 individuals for each studied population. SIFT (http://sift.
jcvi.org/), Polyphen2 (http://genetics.bwh.harvard.edu/pph2/) and MutationTaster (http://www.mutationtaster.
org/) were used for in silico analysis. In addition, XHMM and Conifer were used for the Copy Number Variant 
(CNVs) detection55–57. Only genes that have been reported to have HL as a phenotypic finding in OMIM were 
further selected. Variants meeting these criteria were further annotated based on their presence and pathogenic-
ity information in Human Gene Mutation Database (HGMD) and ClinVar58,59. In addition American College of 
Medical Genetics and Genomics (ACMG) Standards and Guidelines 2015 were used for the variant interpreta-
tion60. Probands who were found to carry variants in SHL genes were subsequently re-evaluated for syndromic 
findings.
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